Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study

被引：0
|
作者：
Kapoor, R. [1 ]
Sellebjerg, F. [2 ]
Hartung, H. -P. [3 ]
Arnold, D. L. [4 ]
Freedman, M. S. [5 ]
Jeffery, D. [6 ]
Miller, A. [7 ]
Edwards, K. R. [8 ]
Singh, C. M. [9 ]
Chang, I. [9 ]
Ren, Z. [9 ]
Sangurdekar, D. [9 ]
Zhu, B. [9 ]
Sheikh, S. [9 ]
Mehta, D. [9 ]
Ho, P. -R. [9 ]
Campbell, N. [9 ]
Edwards, M. [9 ]
Fisher, E. [9 ]
Kieseier, B. C. [9 ]
Rudick, R. A. [9 ]
Plavina, T. [9 ]
机构：
[1] UCL Inst Neurol, London, England
[2] Univ Copenhagen, Danish Multiple Sclerosis Ctr, Rigshosp, Copenhagen, Denmark
[3] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany
[4] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[5] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[6] Piedmont HealthCare, Mooresville, NC USA
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[8] MS Ctr Northeastern New York, Latham, NY USA
[9] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1740
引用
收藏
页码：988 / 988
页数：1
相关论文
共 50 条
  • [31] Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients
    Dalla Costa, G.
    Martinelli, V.
    Furlan, R.
    Finardi, A.
    Sangalli, F.
    Colombo, B.
    Moiola, L.
    Cinque, P.
    Kolb, E.
    Haghikia, A.
    Gold, R.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 368 - 369
  • [32] Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients
    Dalla Costa, Gloria
    Martinelli, Vittorio
    Finardi, Annamaria
    Sangalli, Francesca
    Colombo, Bruno
    Moiola, Lucia
    Cinque, Paola
    Kolb, Eva-Maria
    Haghikia, Aiden
    Gold, Ralf
    Furlan, Roberto
    Comi, Giancarlo
    NEUROLOGY, 2018, 90
  • [33] Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
    Amor, Sandra
    van der Star, Baukje J.
    Bosca, Isabel
    Raffel, Joel
    Gnanapavan, Sharmilee
    Watchorn, Jonathan
    Kuhle, Jens
    Giovannoni, Gavin
    Baker, David
    Malaspina, Andrea
    Puentes, Fabiola
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (10) : 1355 - 1362
  • [34] Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
    Gresle, M. M.
    Liu, Y.
    Dagley, L. F.
    Haartsen, J.
    Pearson, F.
    Purcell, A. W.
    Laverick, L.
    Petzold, A.
    Lucas, R. M.
    Van der Walt, A.
    Prime, H.
    Morris, D. R.
    Taylor, B. V.
    Shaw, G.
    Butzkueven, H.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1209 - 1213
  • [35] Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet
    Oh, Unsong
    Woolbright, Emma
    Lehner-Gulotta, Diana
    Coleman, Rachael
    Conaway, Mark
    Goldman, Myla D.
    Brenton, J. Nicholas
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 73
  • [36] Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
    Jakimovski, Dejan
    Bergsland, Niels
    Dwyer, Michael G.
    Ramasamy, Deepa P.
    Ramanathan, Murali
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    DIAGNOSTICS, 2020, 10 (09)
  • [37] Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis
    Uher, Tomas
    Schaedelin, Sabine
    Benova, Barbora
    Barro, Christian
    Bergsland, Niels
    Dwyer, Michael
    Tyblova, Michaela
    Kucerova, Karolina
    Benkert, Pascal
    Michalak, Zuzanna
    Leppert, David
    Naegelin, Yvonne
    Krasensky, Jan
    Seidl, Zdenek
    Vaneckova, Manuela
    Havrdova, Eva Kubala
    Kappos, Ludwig
    Zivadinov, Robert
    Horakova, Dana
    Kuhle, Jens
    Kalincik, Tomas
    NEUROLOGY, 2019, 92 (15)
  • [38] Serum neurofilament light chain levels predict thalamic volume loss in multiple sclerosis
    Magon, S.
    Schaedelin, S.
    Barro, C.
    Tsagkas, C.
    Chakravarty, M.
    Gaetano, L.
    Naegelin, Y.
    Benkert, P.
    Amann, M.
    Parmar, K.
    Papadopoulou, A.
    Wuerfel, J.
    Yaldizli, O.
    Oechtering, J.
    Leppert, D.
    Sprenger, T.
    Kappos, L.
    Granziera, C.
    Kuhle, J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 501 - 502
  • [39] No change on serum neurofilament light chain concentrations in patients with multiple sclerosis switching from 4 to 6 weeks interval between natalizumab infusions
    Johnsson, M.
    Farman, H.
    Lycke, J.
    Novakova, L.
    Malmestrom, C.
    Zetterberg, H.
    Blennow, K.
    Axelsson, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 764 - 764
  • [40] Evaluation of neurofilament heavy chain levels in progressive multiple sclerosis patients: preliminary results
    Kaymakamzade, B.
    Kurne, A. Tuncer
    Tumani, H.
    Lehmensiek, V.
    Sayat, G.
    Karabudak, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S453 - S453
12345